Work

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide

Year: 2014

Type: article

Abstract: In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients with micrometastases, and thus deserves further investigation.

Source: OncoImmunology

DOI: 10.4161/onci.28247

Authors: Xin Chen, Lalage M Wakefield, Joost J Oppenheim

Institutions: Frederick National Laboratory for Cancer Research, National Cancer Institute, Center for Cancer Research, Leidos Biomedical Research Inc. (United States)

Language: English

Topic: TGF-β signaling in diseases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913